Bo Ram Sung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo Ram Sung has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Byung Soo Kwan
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Republic of Korea
2 shared publications - Kwang Min Kim
Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
2 shared publications - Bo Kyeong Lee
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
1 shared publication - Cheon Hoo Jeon
Division of Infectious Diseases, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea; Center for Infection Prevention and Control, Samsung Changwon Hospital, Changwon, Republic of Korea
1 shared publication - Jun Young Kim
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Republic of Korea
1 shared publication - Jung Won Lee
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
1 shared publication
Latest Publications
- Open Access
- 12 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (50) , e46449
Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study
Direct-acting antiviral (DAA) therapy is now the recommended standard for chronic hepatitis C (CHC), demonstrating remarkable efficacy. Nonetheless, there is a relative lack of information concerning the sustained, long-term consequences of DAA treatment. Therefore, this study sought to investigate the long-term impact of DAA therapy on patients with CHC. We conducted a retrospective review of CHC patients who received DAA therapy at Samsung Changwon Hospital. Patients with preexisting hepatocellular carcinoma (HCC) and those lost to follow-up were excluded. Demographic, clinical, and virological data were analyzed, focusing on DAA treatment outcomes, liver fibrosis, and the relationship with HCC development. A total of 223 patients were included: 59.5% with CHC genotype 1, 93.3% treatment-naïve, and 26.5% with liver cirrhosis (LC). Treatment included asunaprevir and daclatasvir in 46.2%, with 46.2% receiving a 12-week regimen. Sustained virological response at 12 weeks (SVR12) was achieved in 97.8%, with 5 treatment failures. Post-treatment, APRI scores < 0.7 increased (68.2% vs 87.7%, P < .001), as did FIB-4 scores < 3.25 (60.1% vs 80.3%, P < .001). During follow-up, 9 patients developed HCC, with serum sodium identified as a risk factor (odds ratio: 0.6; confidence interval: 0.41–0.88; P = .008). DAA treatment effectively treats CHC and reduces liver fibrosis. However, further research is warranted to better understand and predict the development of HCC.
- 12 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (50) , e46449
Open AccessEvaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study
Direct-acting antiviral (DAA) therapy is now the recommended standard for chronic hepatitis C (CHC), demonstrating remarkable efficacy. Nonetheless, there is a relative lack of information concerning the sustained, long-term consequences of DAA treatment. Therefore, this study sought to investigate the long-term impact of DAA therapy on patients with CHC. We conducted a retrospective review of CHC patients who received DAA therapy at Samsung Changwon Hospital. Patients with preexisting hepatocellular carcinoma (HCC) and those lost to follow-up were excluded. Demographic, clinical, and virological data were analyzed, focusing on DAA treatment outcomes, liver fibrosis, and the relationship with HCC development. A total of 223 patients were included: 59.5% with CHC genotype 1, 93.3% treatment-naïve, and 26.5% with liver cirrhosis (LC). Treatment included asunaprevir and daclatasvir in 46.2%, with 46.2% receiving a 12-week regimen. Sustained virological response at 12 weeks (SVR12) was achieved in 97.8%, with 5 treatment failures. Post-treatment, APRI scores < 0.7 increased (68.2% vs 87.7%, P < .001), as did FIB-4 scores < 3.25 (60.1% vs 80.3%, P < .001). During follow-up, 9 patients developed HCC, with serum sodium identified as a risk factor (odds ratio: 0.6; confidence interval: 0.41–0.88; P = .008). DAA treatment effectively treats CHC and reduces liver fibrosis. However, further research is warranted to better understand and predict the development of HCC.
- Open Access
- 31 January 2025
- Published by Korean Pancreatobiliary Association in The Korean Journal of Pancreas and Biliary Tract
- Vol. 30 (1) , 26-30
Two Cases of Pancreatobiliary Disease Complications Treated Using Over-the-Scope Clip
The over-the-scope clip (OTSC) system is a powerful full-thickness suturing device used for closing refractory bleeding, perforations, and fistulas in gastrointestinal diseases, offering greater force than conventional clips. Here, we report two cases of pancreatobiliary disease treated using OTSC. The first case involved the successful OTSC ligation of a colonic fistula caused by necrotizing pancreatitis, and the second was a duodenal perforation due to stent migration, which was also successfully treated with OTSC. These cases indicate that OTSC can be beneficial for pancreatobiliary diseases, potentially eliminating the need for surgery when endoscopic treatment is successful.
- 31 January 2025
- Published by Korean Pancreatobiliary Association in The Korean Journal of Pancreas and Biliary Tract
- Vol. 30 (1) , 26-30
Open AccessTwo Cases of Pancreatobiliary Disease Complications Treated Using Over-the-Scope Clip
The over-the-scope clip (OTSC) system is a powerful full-thickness suturing device used for closing refractory bleeding, perforations, and fistulas in gastrointestinal diseases, offering greater force than conventional clips. Here, we report two cases of pancreatobiliary disease treated using OTSC. The first case involved the successful OTSC ligation of a colonic fistula caused by necrotizing pancreatitis, and the second was a duodenal perforation due to stent migration, which was also successfully treated with OTSC. These cases indicate that OTSC can be beneficial for pancreatobiliary diseases, potentially eliminating the need for surgery when endoscopic treatment is successful.